11/12/2025
Big news for women in menopause!
The FDA has updated its guidance on hormone therapy 💊
New research shows that starting treatment before age 60 or within 10 years of menopause can offer more benefits than risks — including better heart, bone, and brain health.
The old “lowest dose for the shortest time” rule? ➡️ Now replaced with personalized treatment based on each woman’s needs.
And now, in detail:
The Food and Drug Administration (FDA) is updating the labeling for menopausal hormone therapy (MHT) to reflect newer evidence showing that when therapy is started in women younger than 60 or within 10 years of menopause onset, the benefit-risk balance is more favorable. 
The revisions include removing “boxed warnings” for systemic estrogen and combined estrogen-progestogen therapies (except when unopposed estrogen is used in women with a uterus), and shifting away from the “lowest dose for shortest duration” blanket advice toward individualized decision-making. 
The article underscores that earlier initiation of MHT is associated with reduced risks of cardiovascular disease, fractures, cognitive decline and Alzheimer-disease — benefits that had been under-recognized. 
In short: The new labeling aims to better differentiate among formulations, timing, and patient age — enabling more tailored and informed hormone therapy discussions between clinicians and menopausal women.

(Full article in comment)
